Health Secretary Unveils Psychiatric Deprescribing Plan as NIH Mental Health Grants Face 40% Cut Threat
Updated
Updated · STAT · Jul 17
Health Secretary Unveils Psychiatric Deprescribing Plan as NIH Mental Health Grants Face 40% Cut Threat
2 articles · Updated · STAT · Jul 17
Summary
At a May MAHA summit, the health secretary rolled out a psychiatric deprescribing plan that would have SAMHSA study prescribing trends, issue fact sheets, and convene an expert panel over the summer.
Medicare would also clarify payment for clinicians tapering patients off medication, while federal webinars would promote prevention and “holistic” care as part of an anti-overmedicalization agenda.
The broader concern is that the initiative recasts mental health policy away from evidence-based treatment toward lifestyle and wellness, potentially making medication maintenance harder without formally banning drugs.
That shift comes as the administration has already terminated hundreds of NIH grants in early 2025, with NIMH losing the most, and has proposed slashing NIH by roughly 40%.
Critics argue the combination of weaker research funding and safety-net cuts — including 700,000 children losing SNAP in 12 states and lower WIC benefits — could leave patients with schizophrenia, bipolar disorder, and severe depression most exposed.
Is America's new mental health strategy at risk of repeating the mistakes of the past?
With research funding now politicized, what is the future for scientific mental health discovery?
Can a 'wellness' agenda succeed when policies cut access to basic needs like food?
Psychiatric Deprescribing and Federal Funding Instability: The 2026 U.S. Mental Health Policy Crossroads
Overview
In May 2026, the U.S. Department of Health and Human Services launched the Psychiatric Deprescribing Initiative to address concerns about psychiatric overprescribing, especially in children. This comprehensive plan focuses on re-evaluating and optimizing psychiatric medication use by encouraging deprescribing based on clear clinical indicators, with a strong emphasis on pediatric care. HHS agencies are tasked with reviewing current prescription patterns to assess both benefits and harms, aiming to prevent unnecessary medication starts and support careful tapering or discontinuation when appropriate. The initiative seeks to ensure individuals receive the most suitable support and make informed treatment decisions.